Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

GW Pharmaceuticals PLC (NASDAQ:GWPH)

BATS BZX Real-Time Price
As of 10:33am ET
 -0.49 / -0.57%
Today’s Change
Today|||52-Week Range
Health Technology
Pharmaceuticals: Other

Company Description

GW Pharmaceuticals Plc engages in the business of discovering, developing and commercializing novel therapeutics from proprietary cannabinoid product platform in a broad range of disease areas. The company operates through the following segments: Commercial, Sativex Research & Development and Pipeline Research & Development. The Commercial segment promotes Sativex through strategic collaborations with major pharmaceutical companies for the currently approved indication of spasticity due to multiple sclerosis. The Sativex Research & Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research & Development segment seeks to develop cannabinoid medications other than Sativex, which are using the Group's proprietary cannabinoid technology platform. GW Pharmaceuticals was founded by Geoffrey W. Guy and Brian Whittle in 1998 and is headquartered in Salisbury, the United Kingdom.

Contact Information

GW Pharmaceuticals Plc
Sovereign House
Cambridge Cambridgeshire CB24 9BZ
Investor Relations:
(917) 280-2424



Mutual fund holders44.53%
Other institutional23.40%
Individual stakeholders--

Top Executives

Justin D. GoverChief Executive Officer & Executive Director
Christopher John ToveyChief Operating Officer & Executive Director
Adam David GeorgeCFO, Secretary & Executive Director
Richard PottsDirector-Clinical Operations
Colin StottDirector-Research & Development Operations